These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11285159)

  • 61. [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].
    Cervero M; Torres R; Jusdado JJ; Rodríguez-Rosado R; Del Alamo M; García-Benaya E
    Enferm Infecc Microbiol Clin; 2006; 24(7):426-30. PubMed ID: 16956530
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
    Uglietti A; Maserati R
    Expert Opin Investig Drugs; 2011 Apr; 20(4):559-65. PubMed ID: 21391888
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
    An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
    Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
    HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE; Johnson GM; Stanley K; Yong FH; Keller A; O'Donnell KJ; Brouwers P; Mitchell WG; Yogev R; Wara DW; Wiznia A; Mofenson L; McNamara J; Spector SA
    J Pediatr; 1998 Oct; 133(4):500-8. PubMed ID: 9787687
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
    Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
    Negredo E; Moltó J; Burger D; Viciana P; Ribera E; Paredes R; Juan M; Ruiz L; Puig J; Pruvost A; Grassi J; Masmitjà E; Clotet B
    AIDS; 2004 Feb; 18(3):459-63. PubMed ID: 15090798
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.
    Benito JM; López M; Ballesteros C; Lozano S; Capa L; Barreiro P; Sempere J; Gonzalez-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):734-43. PubMed ID: 16910828
    [TBL] [Abstract][Full Text] [Related]  

  • 71. L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.
    Moretti S; Famularo G; Marcellini S; Boschini A; Santini G; Trinchieri V; Lucci L; Alesse E; De Simone C
    Antioxid Redox Signal; 2002 Jun; 4(3):391-403. PubMed ID: 12215207
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
    Foli A; Maserati R; Minoli L; Wainberg MA; Gallo RC; Lisziewicz J; Lori F
    AIDS; 1998 Jun; 12(9):1113-4. PubMed ID: 9662215
    [No Abstract]   [Full Text] [Related]  

  • 73. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
    Moore RD; Keruly JC; Chaisson RE
    AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.
    Flandre P; Chappey C; Marcelin AG; Ryan K; Maa JF; Bates M; Seekins D; Bernard MC; Calvez V; Molina JM
    J Infect Dis; 2007 Feb; 195(3):392-8. PubMed ID: 17205478
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
    Lisziewicz J; Foli A; Wainberg M; Lori F
    Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients.
    Biron F; Ponceau B; Bouhour D; Boibieux A; Verrier B; Peyramond D
    J Acquir Immune Defic Syndr; 2000 Dec; 25(4):329-36. PubMed ID: 11114833
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    Zhou XJ; Sheiner LB; D'Aquila RT; Hughes MD; Hirsch MS; Fischl MA; Johnson VA; Myers M; Sommadossi JP
    Antimicrob Agents Chemother; 1999 Jan; 43(1):121-8. PubMed ID: 9869576
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
    De Boer RJ; Boucher CA; Perelson AS
    AIDS; 1998 Sep; 12(13):1567-70. PubMed ID: 9764774
    [No Abstract]   [Full Text] [Related]  

  • 80. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
    Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
    Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.